Background : Patients with acute ischemic stroke who had early neurological improvement had better functional outcome. The purpose of this study was to determine factors associated with early clinical improvement and early worsening in patients with acute ischemic stroke treated with intravenous thrombolysis. Patients and Methods : Patients treated with intravenous recombinant tissue plasminogen activator (rtPA) between August 2008 and November 2010 were the subjects of this study. Early improvement was defined by marked, clinical improvement or complete recovery at 24 h (National Institutes of Health Stroke Scale (NIHSS) 0-4 at 24 h). Early worsening was defined by an increase in NIHSS ≥1 from baseline. The baseline characteristics were co...
<p><strong>Background:</strong> Intravenous recombinant tissue plasminogen activator (rt-PA) is the ...
BACKGROUND: In recent years, the medical literature has shown that statin treatment before and in th...
BACKGROUND AND PURPOSE: We previously reported increased benefit and reduced mortality after ultra-e...
Background : Patients with acute ischemic stroke who had early neurological improvement had better f...
Objective : The aim of this study was to determine the factors associated with early neurological im...
BACKGROUND: Intravenously administered tissue plasminogen activator (IV tPA) remains the only approv...
International audienceOBJECTIVE: To evaluate whether very early neurologic improvement (VENI) after ...
Background : Despite the increasing use of recombinant tissue plasminogen activator (rt-PA) in acute...
A large number of parameters have been identified as predictors of early outcome in patients with ac...
The objective of our study is to detect the patient group that will most benefit from intravenous (I...
Background: Intravenous recombinant tissue plasminogen activator (rt-PA) thrombolysis therapy has be...
INTRODUCTION: This study aimed to discuss the results of the intravenous thrombolytic treatment (IV-...
Introduction: Evidence of the intravenous tissue plasminogen activator (tPA) efficacy beyond the 4.5...
Background: To determine whether it is possible to predict intravenous thrombolytic therapy (IVT) ou...
Abstract Introduction: Vascular disorders represent a major cause of mortality worldwide, with isch...
<p><strong>Background:</strong> Intravenous recombinant tissue plasminogen activator (rt-PA) is the ...
BACKGROUND: In recent years, the medical literature has shown that statin treatment before and in th...
BACKGROUND AND PURPOSE: We previously reported increased benefit and reduced mortality after ultra-e...
Background : Patients with acute ischemic stroke who had early neurological improvement had better f...
Objective : The aim of this study was to determine the factors associated with early neurological im...
BACKGROUND: Intravenously administered tissue plasminogen activator (IV tPA) remains the only approv...
International audienceOBJECTIVE: To evaluate whether very early neurologic improvement (VENI) after ...
Background : Despite the increasing use of recombinant tissue plasminogen activator (rt-PA) in acute...
A large number of parameters have been identified as predictors of early outcome in patients with ac...
The objective of our study is to detect the patient group that will most benefit from intravenous (I...
Background: Intravenous recombinant tissue plasminogen activator (rt-PA) thrombolysis therapy has be...
INTRODUCTION: This study aimed to discuss the results of the intravenous thrombolytic treatment (IV-...
Introduction: Evidence of the intravenous tissue plasminogen activator (tPA) efficacy beyond the 4.5...
Background: To determine whether it is possible to predict intravenous thrombolytic therapy (IVT) ou...
Abstract Introduction: Vascular disorders represent a major cause of mortality worldwide, with isch...
<p><strong>Background:</strong> Intravenous recombinant tissue plasminogen activator (rt-PA) is the ...
BACKGROUND: In recent years, the medical literature has shown that statin treatment before and in th...
BACKGROUND AND PURPOSE: We previously reported increased benefit and reduced mortality after ultra-e...